Strategic Directions & Recommendations: Diversity, Equity and Inclusion Scoping Review
February 7, 2022
Related
Early and Often: Reimagining patient community engagement to improve clinical trials feasibility
The Global Genes Corporate Alliance has developed a new white paper that shows the transformative role of […]
Read moreContinuing Advocacy and Expanding Research Efforts: Global Genes 2023 Impact Report
To our community members: For both the rare disease community and Global Genes, 2023 marked a year […]
Read moreGlobal Genes 2023 RARE Impact Grants Report
Over the past decade, Global Genes’ RARE Impact Grant Program has provided grants to rare disease patient […]
Read moreNEXT Report 2024: Rewriting the Rules
Over the past year, technological advances in rare disease drug and therapy development, coupled with the tenacity of rare disease patients and advocates, have prevailed despite the challenges of financial difficulties in biopharma. Next-generation patient advocates continue to take an active role in drug development, as outlined in the 2024 NEXT Report.
Read moreGlobal Genes 2022 RARE Impact Grants Report
Over the past decade, Global Genes’ RARE Impact Grant Program has provided funding opportunities for rare patient […]
Read moreGlobal Genes Impact Report: Building on a Successful 2022
To our community members: The year 2022 was a significant one for the rare disease community as […]
Read moreRARE-X Insights & Recommendations for Organizational DEI Strategies Study
Ensuring diversity, equity, and inclusion in rare disease organizations requires focused programs that engage all stakeholders. A […]
Read moreRARE Health Equity Report: Building a More Inclusive Rare Disease Community
For communities of color and other minoritized populations, finding and connecting with others in their disease community, […]
Read moreNEXT 2023: The Rise of the Impatient Advocate
As Global Genes begins the year with an expanded focus on enabling next-generation patient advocacy, following its […]
Read more